NCT04920578

A Study of JNJ-69095897 in Healthy Participants

A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-69095897 in Healthy Participants

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-69095897 versus placebo and to characterize the pharmacokinetic (PK) of JNJ-69095897 in blood, plasma, cerebrospinal fluid (CSF) and urine after single or divided oral dose administration in healthy participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-69095897	JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
OTHER	Placebo	Matching placebo will be administered orally in Parts 1 and 3.

Timeline

• Start date: 2021-06-16
• Primary completion: 2023-01-27
• Completion: 2023-02-27
• First posted: 2021-06-10
• Last updated: 2025-04-27

Locations

1 site across 1 country: Netherlands